Skip to main content
How the Immune System Learns from Harmless Particles

News categories: Publication

How the Immune System Learns from Harmless Particles

Our lungs are bombarded by all manner of different particles every single day. Whilst some are perfectly safe for us, others—known as pathogens—have the potential to make us ill. The immune system trains its response whenever it encounters such a pathogen. Yet researchers at the University of Bonn have now shown that even harmless particles help to improve the immune response and have published their results in the journal “Nature Immunology.”

An adult takes around 12 breaths a minute, filling their lungs with life-giving air. But they also breathe in all kinds of particles: harmless, germ-free organisms as well as fungal spores and pathogenic bacteria and viruses. “Whether we’re on public transport where people are coughing or in air-conditioned rooms where the air is full of fungal spores, our lungs are constantly being impacted by our environment,” says Professor Andreas Schlitzer, head of the Quantitative Systems Biology working group in the Life & Medical Sciences Institute (LIMES) at the University of Bonn. “It’s a challenge that the immune system in our lungs has to cope with throughout our lives. It has to adapt to ever-changing requirements, distinguish harmless particles from dangerous ones and react accordingly.”

However, the macrophages—cells of the innate immune system that are responsible for this task—know what they have to do. These “scavenger cells” identify pathogenic particles, destroy them reliably—for the most part—and store the attackers’ details in the immune system’s memory so that they can respond even more effectively next time. But what do the macrophages do with information on harmless particles? This was the question investigated by the working group led by Andreas Schlitzer, who is also a member of the Cluster of Excellence ImmunoSensation2 and the Life and Health Transdisciplinary Research Area at the University of Bonn. “The macrophages could simply forget all about innocuous particles because they don’t do us any harm,” Schlitzer explains. “However, we suspected that they retain information on them anyway and incorporate this knowledge into subsequent immune responses.”

Immune response modified by fungal spores

To test their idea, the researchers made mice breathe in beta-glucan, a sugar found inside the cell wall of a fungus called candida. “We’re exposed to these fungal spores all the time in our daily lives,” Schlitzer points out. “You get them in particularly high concentrations inside rooms with air-conditioning, for example, which are ideal places for them to live.” Although this particular fungus is perfectly safe for healthy people, it can put those with a weakened immune system—due to conditions such as HIV, for instance—at risk of serious illness.

The researchers then used high-dimensional single-cell technologies to study how the mice’s immune system reacted to harmful pathogens. They found that mice that were exposed to the beta-glucan first before being infected with legionella bacteria responded differently to the pathogens than those that were not. “The mice were resistant to the legionella infection or, to put it another way, managed to recover better thanks to their modified immune response,” Schlitzer explains, summing up the findings.

In order to adapt the immune response after coming into contact with harmless particles, macrophages use specific proteins that also play a role in diseases such as Alzheimer’s and obesity. Says Schlitzer: “If we’re able to modulate macrophages in specific ways, they could serve as ‘dials’ that we could tweak in order to treat these conditions.” This is what his working group will be researching going forward.

 

Publication:

Theobald H., Bejarano D.A., Katzmarski N., Haub J., et al. (2024)

Apolipoprotein E controls Dectin-1-dependent development of monocyte-derived alveolar macrophages upon pulmonary β-glucan-induced inflammatory adaptationin

Nature Immunology, DOI: 10.1038/s41590-024-01830-

Contact:

Prof. Dr. Andreas Schlitzer

Life & Medical Sciences Institute (LIMES)

University of Bonn

Phone: +49 228 73-62738

Email: aschlitz@uni-bonn.de

Press contact:

Katrin Piecha

Science editor at the University of Bonn

E-Mail: kpiecha@uni-bonn.de

Related news

Dr. Clivia Lisowski und Prof. Christian Kurts

News categories: Publication

Immune cells in the liver help pigeons navigate

How do pigeons find their way home safely over distances of many kilometers? A research team from the University Hospital Bonn (UKB), the University of Bonn, the University of Duisburg-Essen, and the Max Planck Institute for Behavioral Biology has now discovered a previously unknown mechanism: specific immune cells in the liver may help the birds detect the Earth’s magnetic field. The findings have now been published in the journal Science.
View entry
News Icon

News categories: Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry
Wissenschaftler

News categories: Publication

Driver of inflammation after mild head injury

Mild traumatic brain injuries can lead to persistent memory problems and an increased risk of dementia. Yet, effective therapies to counteract these long-term consequences are still lacking. Dr. Dr. Sergio Castro-Gomez, Early Career Research Group Leader at the Institute of Physiology II of the University Hospital Bonn has discovered together with colleagues that the ASC protein. The research team hopes to identify new targets for future therapeutic strategies. The study, published in the Journal of Clinical Investigation, lays the foundation for upcoming clinical trials.
View entry

Back to the news overview